These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11397626)

  • 41. Resistance to quinolones in pathogens causing urinary tract infections.
    Kapoor H; Aggarwal P
    J Commun Dis; 1997 Sep; 29(3):263-7. PubMed ID: 9465532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary tract-derived Escherichia coli resistant to co-trimoxazole in Japan, where the drug is seldom used for treating acute urinary tract infections.
    Ishihara S; Yokoi S; Masue N; Yamada T; Minamidate Y; Yasuda M; Nakano M; Deguchi T
    J Antimicrob Chemother; 2002 May; 49(5):881-2. PubMed ID: 12003990
    [No Abstract]   [Full Text] [Related]  

  • 43. [Shorten time of treatment in lower urinary tract infection in women and don't use quinolones!].
    Cars O; Struwe J; Norman C; Sandberg T
    Lakartidningen; 2008 Apr 9-15; 105(15):1114-5. PubMed ID: 18561756
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli.
    Baskin H; Doğan Y; Bahar IH; Yuluğ N
    Int J Antimicrob Agents; 2002 Jan; 19(1):79-82. PubMed ID: 11814773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ANTIBIOTIC SUSCEPTIBILITY OF ORGANISMS CAUSING URINARY TRACT INFECTION IN PATIENTS PRESENTING AT KENYATTA NATIONAL HOSPITAL, NAIROBI.
    Magale HI; Kassim IA; Odera SA; Omolo MJ; Jaoko WG; Jolly PE
    East Afr Med J; 2015 Jul; 92(7):333-337. PubMed ID: 27867208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Guidelines for management of urinary tract infections in adults--an initiative].
    Wagenlehner F; Sester U; Naber K
    Urologe A; 2006 Apr; 45(4):464-6. PubMed ID: 16528537
    [No Abstract]   [Full Text] [Related]  

  • 47. [Nosocomial urinary infections. Comparison of experience in two urology centers].
    Ambruoso G; Aimè G; Borsa R; Salzarulo M; Fontana G
    Minerva Urol Nefrol; 1994 Sep; 46(3):167-9. PubMed ID: 7801213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.
    Sotto A; De Boever CM; Fabbro-Peray P; Gouby A; Sirot D; Jourdan J
    J Clin Microbiol; 2001 Feb; 39(2):438-44. PubMed ID: 11158087
    [TBL] [Abstract][Full Text] [Related]  

  • 49. USA resistance patterns among UTI pathogens.
    Thomson KS; Sanders WE; Sanders CC
    J Antimicrob Chemother; 1994 May; 33 Suppl A():9-15. PubMed ID: 7928840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro study of the susceptibility of Escherichia coli to mecillinam.
    Bjerager L; Skov R; Frimodt-Møller N
    J Antimicrob Chemother; 2000 Jun; 45(6):920-1. PubMed ID: 10837453
    [No Abstract]   [Full Text] [Related]  

  • 51. Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections.
    Casellas JM; Tome G; Exeni R; Grimoldi I; Goldberg M; Farinati AE
    Pathol Biol (Paris); 1993 Apr; 41(4):385-91. PubMed ID: 8233640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nitrofurantoin: an effective and ignored antimicrobial.
    Arya SC; Agarwal N; Agarwal S
    Int J Antimicrob Agents; 2006 Apr; 27(4):354-5. PubMed ID: 16531014
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of ciprofloxacin on adhesive properties of non-P mannose-resistant uropathogenic Escherichia coli isolates.
    Balagué C; Fernández L; Pérez J; Grau R
    J Antimicrob Chemother; 2003 Feb; 51(2):401-4. PubMed ID: 12562710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial activity data in support of nitrofurantoin three times per day.
    Amábile-Cuevas CF; Arredondo-García JL
    J Antimicrob Chemother; 2011 Jul; 66(7):1652-3. PubMed ID: 21525023
    [No Abstract]   [Full Text] [Related]  

  • 55. Quinolones: a new class of antimicrobial agents with wide potential uses.
    Neu HC
    Med Clin North Am; 1988 May; 72(3):623-36. PubMed ID: 3280910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
    Gales AC; Gordon KA; Wilke WW; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):61-4. PubMed ID: 10744370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Asymptomatic bacteriuria and symptomatic urinary tract infections (UTI) in patients with diabetes mellitus in Tikur Anbessa Specialized University Hospital, Addis Ababa, Ethiopia.
    Yeshitela B; Gebre-Selassie S; Feleke Y
    Ethiop Med J; 2012 Jul; 50(3):239-49. PubMed ID: 23409407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluoroquinolone-Resistant Sequence Type 131 Subgroups O25b and O16 Among Extraintestinal Escherichia coli Isolates from Community-Acquired Urinary Tract Infections.
    Hefzy EM; Hassuna NA
    Microb Drug Resist; 2017 Mar; 23(2):224-229. PubMed ID: 27214282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections.
    Aguiar JM; Chacon J; Canton R; Baquero F
    J Antimicrob Chemother; 1992 Mar; 29(3):349-50. PubMed ID: 1592705
    [No Abstract]   [Full Text] [Related]  

  • 60. [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
    Weber P; Dib C; Durand C; Moniot-Ville N
    Pathol Biol (Paris); 2005 Mar; 53(2):125-8. PubMed ID: 15708658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.